Analyst Price Target is $12.50
▲ +45.52% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for POINT Biopharma Global in the last 3 months. The average price target is $12.50, with a high forecast of $17.00 and a low forecast of $8.00. The average price target represents a 45.52% upside from the last price of $8.59.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in POINT Biopharma Global.
POINT Biopharma Global Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of radioligand therapies for the treatment of cancer. Its products include PNT2001, a PSMA radioligand that is in preclinical studies for early stage prostate cancer treatment; PNT2002, which is in Phase 3 studies to evaluate superiority to the standard of care in mCRPC patients; PNT2003, a somatostatin-targeted radioligand therapy that is in Phase 3 trials for the treatment of patients with somatostatin receptor-positive neuroendocrine tumors; and PNT2004, a radioligand that targets fibroblast activation protein-a. The company is based in Indianapolis, Indiana.